MedTrace Logo

Prevent Diabetic Kidney Disease Among Egyptians

NCT06071208 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2023-10-10

No results posted yet for this study

Summary

Study of the possibility to prevent the development of Diabetic kidney disease in type 2 diabetic patients

Conditions

  • Diabetes Mellitus Without Complication

Interventions

DRUG

Gliflozin

to study whether the use of gliflozin prevented diabetic complications

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • NewGiza University

    collaborator OTHER

  • Fayoum University

    lead OTHER

Principal Investigators

  • Usama Sharaf El Din, MD · Cairo University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-14
Primary Completion
2028-10-14
Completion
2028-12-14
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06071208 on ClinicalTrials.gov